Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator.
The Epstein-Barr virus basic leucine zipper transcriptional activator ZEBRA was shown recently to cross the outer membrane of live cells and to accumulate in the nucleus of lymphocytes. We investigated the potential application of the Epstein-Barr virus trans-activator ZEBRA as a transporter protein to facilitate transduction of cargo proteins. Analysis of different truncated forms of ZEBRA revealed that the minimal domain (MD) required for internalization spans residues 170-220. MD efficiently transported reporter proteins such as enhanced green fluorescent protein (EGFP) and beta-galactosidase in several normal and tumor cell lines. Functionality of internalized cargo proteins was confirmed by beta-galactosidase activity in transduced cells, and no MD-associated cell toxicity was detected. Translocation of MD through the cell membrane required binding to cell surface-associated heparan sulfate proteoglycans as shown by strong inhibition of protein uptake in the presence of heparin. We found that internalization was blocked at 4 degrees C, whereas no ATP was required as shown by an only 25% decreased uptake efficiency in energy-depleted cells. Common endocytotic inhibitors such as nystatin, chlorpromazine, and wortmannin had no significant impact on MD-EGFP uptake. Only methyl-beta-cyclodextrin inhibited MD-EGFP uptake by 40%, implicating the lipid raft-mediated endocytotic pathway. These data suggest that MD-reporter protein transduction occurs mostly via direct translocation through the lipid bilayer and not by endocytosis. This mechanism of MD-mediated internalization is suitable for the efficient delivery of biologically active proteins and renders ZEBRA-MD a promising candidate for therapeutic protein delivery applications.
Rothe
Romy
R
TheREx-HumProTher, TIMC-IMAG Laboratory, CNRS UMR5525, University Joseph Fourier, UFR de Médecine, 38700 La Tronche, France.
Liguori
Lavinia
L
Villegas-Mendez
Ana
A
Marques
Bruno
B
Grunwald
Didier
D
Drouet
Emmanuel
E
Lenormand
Jean-Luc
JL
D001665:Binding Sites / Q000235:genetics; D045744:Cell Line, Tumor; D015342:DNA Probes / Q000235:genetics / Q000378:metabolism; D004705:Endocytosis / Q000187:drug effects; D005434:Flow Cytometry; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism* / Q000493:pharmacokinetics; D006367:HeLa Cells; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D008856:Microscopy, Fluorescence; D009154:Mutation; D011485:Protein Binding; D021381:Protein Transport; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism* / Q000493:pharmacokinetics; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D047392:beta-Cyclodextrins / Q000494:pharmacology; D001616:beta-Galactosidase / Q000235:genetics / Q000378:metabolism* / Q000493:pharmacokinetics
C063676:BZLF1 protein, Herpesvirus 4, Human; D015342:DNA Probes; D011993:Recombinant Fusion Proteins; D015534:Trans-Activators; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D049452:Green Fluorescent Proteins; D001616:beta-Galactosidase
Adv Drug Deliv Rev. 2005 Jan 2;57(1):43-61
15518920
Nat Med. 2004 Mar;10(3):310-5
14770178
J Virol. 1999 Nov;73(11):9029-38
10516009
J Biol Chem. 1997 Jun 20;272(25):16010-7
9188504
EMBO J. 1996 Jun 3;15(11):2748-59
8654372
Cell. 1997 Jan 24;88(2):223-33
9008163
Cell Mol Life Sci. 2006 Aug;63(16):1819-22
16909213
J Biol Chem. 1996 Dec 13;271(50):31799-802
8943219
Biochemistry. 2004 Mar 9;43(9):2438-44
14992581
Curr Pharm Des. 2008;14(34):3686-97
19075744
Bioconjug Chem. 2008 May;19(5):1017-24
18442282
J Control Release. 2008 Mar 20;126(3):217-27
18234390
Biochemistry. 2003 Dec 2;42(47):13787-99
14636045
Biochim Biophys Acta. 2003 Jan 31;1609(2):161-9
12543377
Mol Cell Neurosci. 2004 Oct;27(2):85-131
15485768
Cytometry. 1992;13(2):204-8
1547670
J Biol Chem. 2004 Mar 19;279(12):11425-31
14699109
Adv Cancer Res. 2007;97:81-109
17419942
Annu Rev Biochem. 1998;67:199-225
9759488
J Biol Chem. 2003 Sep 5;278(36):34141-9
12773529
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):608-13
18037528
J Biol Chem. 2007 Sep 14;282(37):27503-27517
17644515
FEBS Lett. 2000 Oct 6;482(3):265-8
11024473
Mol Cell. 2006 Feb 17;21(4):565-72
16483937
Expert Opin Drug Deliv. 2006 Nov;3(6):739-46
17076596
Virus Res. 2005 Jun;110(1-2):187-93
15845271
Virology. 2001 Jun 5;284(2):159-69
11384216
J Biol Chem. 2005 Apr 15;280(15):15300-6
15687490
J Biol Chem. 2001 Feb 2;276(5):3254-61
11024024
Cancer Res. 2002 Apr 1;62(7):2013-8
11929818
J Control Release. 2005 Jan 20;102(1):247-53
15653149
Stroke. 2003 May;34(5):1304-10
12677018
Nat Protoc. 2006;1(2):633-6
17406290
Int J Pharm. 2007 Mar 1;331(2):211-4
17187949
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8
8290579
Cancer Res. 2001 Jan 15;61(2):474-7
11212234
J Biol Chem. 1994 Apr 8;269(14):10444-50
8144628
J Cell Biol. 1996 Dec;135(5):1249-60
8947549
J Mol Recognit. 2003 Sep-Oct;16(5):227-33
14523933
J Gen Virol. 2003 Aug;84(Pt 8):1941-1949
12867624
Mol Ther. 2003 Aug;8(2):284-94
12907151
Bioconjug Chem. 2000 Sep-Oct;11(5):619-26
10995204
Nucleic Acids Res. 2007;35(13):4495-502
17584792
Biol Pharm Bull. 2006 Aug;29(8):1570-4
16880606
Biophys J. 2004 Jan;86(1 Pt 1):254-63
14695267
Trends Microbiol. 2006 Jul;14(7):289-91
16730442
Adv Drug Deliv Rev. 2005 Feb 28;57(4):529-45
15722162
Curr Protoc Protein Sci. 2008 Nov;Chapter 18:18.11.1-18.11.29
19016434